MEOX1 is a clinically relevant novel target in BCSCs and mesenchymal-like cancer cells in PTEN-deficient trastuzumab resistant breast cancer and may serve as target for future drug development.
No mutations were identified in the PAX1 and MEOX1 exons or flanking intronic sequences excluding them as likely causative genes for diaphanospondylodysostosis
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.